Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: OROS-Methylphenidate Clear all
Completed Phase 4 Interventional Results available

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

NCT01552915
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
79
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 4 Interventional Results available

The Effects of ADHD Medication (TEAM) Study

NCT02293655
View directory record Official record
Conditions
ADHD
Interventions
OROS-Methylphenidate (MPH)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 4 Interventional Results available

Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory

NCT00530257
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Placebo, OROS-methylphenidate
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2011 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 3 Interventional Results available

Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth

NCT01109849
View directory record Official record
Conditions
ADHD, Growth
Interventions
behavior therapy, Extended release (ER) methylphenidate product, monitoring, drug holiday, caloric supplement
Behavioral · Drug · Other + 1 more
Lead sponsor
Florida International University
Other
Eligibility
5 Years to 12 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 4 Interventional

Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)

NCT00663442
View directory record Official record
Conditions
ADHD
Interventions
OROS methylphenidate
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
6 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 2 Interventional Results available

Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.

NCT00550147
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Oros Methylphenidate, quetiapine
Drug
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 2Phase 3 Interventional Results available

L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults

NCT01853280
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
L-methylfolate, OROS-Methylphenidate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00880217
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine 80 mg/d, Placebo, OROS methylphenidate HCl 54 mg/d, JNJ-31001074 3 mg/d, JNJ-31001074 1 mg/d, JNJ-31001074 10 mg/d
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
35
States / cities
Little Rock, Arkansas • Lafayette, California • Los Alamitos, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2013 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 4 Interventional

Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy

NCT00323947
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Epilepsy
Interventions
Extended Release Methylphenidate (OROS-Methylphenidate)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 3 Interventional Results available

Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00253747
View directory record Official record
Conditions
ADHD, Smoking
Interventions
Osmotic-Release Methylphenidate, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
6
States / cities
Cambridge, Massachusetts • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2012 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 4 Interventional Results available

Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta

NCT00181714
View directory record Official record
Conditions
ADHD
Interventions
methylphenidate HCl (Concerta)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 17 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults

NCT00302458
View directory record Official record
Conditions
Healthy
Interventions
OROS-Methylphenidate, Immediate Release Methylphenidate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 2Phase 3 Interventional

OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD

NCT02215538
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
OROS methylphenidate, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Sep 2, 2026, 7:27 PM EDT
Terminated Phase 3 Interventional Results available

Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients

NCT00516269
View directory record Official record
Conditions
Breast Cancer, Fatigue, Gastrointestinal Cancer
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 3 Interventional Results available

Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)

NCT00264797
View directory record Official record
Conditions
ADHD, Substance Abuse
Interventions
Methylphenidate (OROS-MPH), Methylphenidate (OROS-MPH) - Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
13 Years to 18 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
12
States / cities
Denver, Colorado • Jacksonville, Florida • St. Petersburg, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 4 Interventional

Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate

NCT00302406
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
methylphenidate hydrochloride, OROS methylphenidate hydrochloride (CONCERTA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

NCT01552902
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
81
States / cities
Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects

NCT00302367
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OROS methylphenidate hydrochloride, immediate release methylphenidate hydrochloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Assessment of Potential Interactions Between IV Methamphetamine and Osmotic-Release Methylphenidate (OROS-MPH)

NCT00603434
View directory record Official record
Conditions
Methamphetamine Dependence, Methamphetamine Abuse
Interventions
OROS-MPH
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate

NCT00593112
View directory record Official record
Conditions
ADHD
Interventions
OROS methylphenidate, No intervention
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 2 Interventional Results available

Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits

NCT01399827
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
Interventions
ADHD Medication, Omega-3 Fatty Acids
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 4 Interventional Results available

Neuroimaging of the Effects of Concerta in the Treatment of ADHD

NCT00778310
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
methylphenidate-OROS, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
9 Years to 25 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults

NCT00302354
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OROS methylphenidate HCl, SODAS methylphenidate HCl
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 2, 2026, 7:27 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults

NCT00301639
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OROS methylphenidate hydrochloride, methylphenidate hydrochloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 2, 2026, 7:27 PM EDT